At a glance
- Ascension Peptides is the only vendor in our public COA database that publishes a per-batch certificate of analysis on every retatrutide lot
- Most recent verified HPLC purity: 99.95% on R-10 lot 03-01260229 (Jan 26, 2026) and 99.88% on R-30 lot 43-01260229 (Jan 26, 2026)
- ENHANCED takes 50% off the Ascension catalog at checkout, including R-10 and R-30
- Retatrutide is not FDA-approved as of May 2026; sale is research-use only. Eli Lilly's TRIUMPH-1/2/3 readouts in 2025 set up an expected NDA in 2026
- Three buyer-verification rules: per-lot COA must match the vial lot number, HPLC purity must be 98% or higher, and the test date should be within the last 12 months
Retatrutide gets searched more than any other research peptide in 2026. The Phase 2 results published in Jastreboff et al. NEJM 2023 (PMID 37356708) showed 24.2% body weight loss at 48 weeks, the largest signal of any peptide in a peer-reviewed obesity trial to that point. Eli Lilly's TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 Phase 3 readouts in 2025 confirmed the magnitude in obesity, type 2 diabetes, and obesity with cardiovascular risk, and an FDA submission is widely expected in 2026.
Until that approval lands, the only legal route for retatrutide is research use, which means picking a vendor with a documented quality story is the entire decision. This guide covers the buyer side: where to source retatrutide with a verifiable certificate of analysis, how to read the COA before you place the order, what the legal framing looks like in May 2026, and how to spot the listings worth avoiding.
Everything below is research-use language. Retatrutide is not FDA-approved and not for human consumption. The discussion that follows assumes a research context.
Quick verdict
For most readers comparing vendors right now, Ascension Peptides is the most defensible pick. It is the only vendor in our public COA database for retatrutide that publishes a per-batch certificate of analysis on every lot it ships, with third-party HPLC purity reports running 99.86–99.95% on the most recent R-10 and R-30 batches. The discount code ENHANCED takes 50% off the Ascension catalog at checkout.
If you want to see the full comparison across the rest of the field (Sports Technology Labs, Direct Peptides, Limitless Biotech, Swiss Chems), the retatrutide lab-tests page lists every record we have side by side, sorted by purity.
Why retatrutide is a different conversation than tirzepatide or semaglutide
Retatrutide is a triple agonist. The molecule activates GLP-1, GIP, and glucagon receptors at the same time. The mechanistic justification is direct: GLP-1 agonism suppresses appetite and improves glucose handling, GIP agonism amplifies insulin action and modulates fat handling, and glucagon agonism increases energy expenditure. The combination produced 24.2% weight loss at 48 weeks in the Phase 2 obesity trial (Jastreboff et al. NEJM 2023, PMID 37356708), versus tirzepatide's roughly 21% at 72 weeks in SURMOUNT-1 and semaglutide's roughly 15% at 68 weeks in STEP-1. The triple-agonist data also came in earlier in the dosing curve.
For the side-by-side mechanism and trial readouts, see the retatrutide vs tirzepatide vs semaglutide comparison. For the dosing ramp specifically, the 12-week titration protocol covers what the trial actually used.
The relevant point for buyers: the demand for retatrutide is now the highest in the GLP-1 category, and that demand has produced both legitimate research-grade vendors and a much larger shadow market of resellers that don't publish COAs. The next sections separate the two.
How to verify a retatrutide vendor in 2026
Three checks. If a vendor fails any of them, the listing is not research-grade.
1. Per-batch certificate of analysis matching the vial lot
The defining quality signal is whether the vendor publishes a third-party COA tied to a specific lot number. Marketing-grade purity claims like "≥99% HPLC" without a per-batch document are a brand statement, not evidence about the bottle in your hand.
Ascension's public COA library lists each retatrutide lot it has ever shipped, with the lot number, test date, and integrated HPLC peak purity printed on the document. When the vial arrives, the lot stamped on the label should match a specific certificate in that library. If it doesn't match, ask before opening.
2. HPLC purity, not "≥99%"
Quantitative HPLC reports a specific number with two decimal places. "99.79%" is a real measurement. "≥99%" is a marketing target. The two have different epistemic weight.
Across the records we track for retatrutide, the verified HPLC numbers cluster between 99.86% and 99.95%. Anything below 98% deserves explanation; anything below 95% is below the analytical threshold for research-grade material.
3. Recent test date
A COA from three years ago describes a different lot than what is in stock today. Recent batch dates (within the last 12 months) are the norm at vendors with active QC. Watch for vendors that link to one historical certificate and reuse it indefinitely.
Vendor comparison
The full live data table sits at /lab-tests/retatrutide. Snapshot of what's in the database as of May 2026:
| Vendor | Format | Most recent purity | Test date | COA tier |
|---|---|---|---|---|
| Ascension Peptides (R-30) | Injectable vial | 99.88% | 2026-01-26 | Per-lot COA |
| Ascension Peptides (R-10) | Injectable vial | 99.94% | 2026-01-28 | Per-lot COA |
| Ascension Peptides (R-30 prior) | Injectable vial | 99.86% | 2025-10-29 | Per-lot COA |
| Direct Peptides | Injectable vial | ≥99% | (vendor spec) | Vendor spec |
Sports Technology Labs and Limitless Biotech do not currently list retatrutide as an active product line.
The COA-tier distinction matters more than the headline number. Ascension publishes the actual document; Direct Peptides publishes a marketing claim plus a generic statement about third-party testing. Both can be accurate, but only one ships with the document attached.
Reconstitution and dosing context
The TRIUMPH program titrated from 2 mg weekly up to 12 mg weekly over 12 weeks. The full schedule lives at the retatrutide 12-week titration protocol. The reconstitution math (vial mg, bacteriostatic water mL, syringe units per dose) is covered by the reconstitution calculator and the peptide reconstitution guide. For the broader dosing reference, the retatrutide dosage chart gathers protocol variants in one place.
A practical note for vial selection: at the higher end of the TRIUMPH ramp (8–12 mg weekly), an R-30 vial yields fewer reconstitution events per cycle than an R-10 vial. R-10 has a small handling advantage in the first 4–6 weeks of titration. Most active researchers stock both.
Discount codes that actually apply
| Vendor | Code | Discount | Applies to |
|---|---|---|---|
| Ascension Peptides | ENHANCED | 50% off | Entire catalog including R-10 and R-30 |
| Limitless Biotech | ENHANCED | 15% off | Oral capsules and nasal sprays only |
The Ascension code stacks onto retatrutide directly. Limitless does not currently sell retatrutide in any format, so its code does not apply to this compound. Bookmark both for adjacent shopping.
Legal status in May 2026
Retatrutide is investigational. As of May 2026, the FDA has not approved retatrutide for any indication, and it is not available by prescription. Eli Lilly is expected to file an NDA in 2026 based on the TRIUMPH Phase 3 readouts; an approval decision typically arrives 10–12 months after submission, which puts a plausible label launch in 2027.
In the interim:
- Sale of retatrutide is permitted in the United States for research use only, not human consumption. This is the channel research-peptide vendors operate in.
- Compounding pharmacies cannot legally compound retatrutide for prescription dispensing because the FDA has not added it to the 503A bulks list and there is no approved drug.
- Some patient-finance telehealth services list "retatrutide" or unbranded GLP-1 protocols. Read carefully. Most of those services are routing to compounded tirzepatide or semaglutide under a label that says retatrutide.
- The standard disclosure on every research-grade vendor we track says explicitly that the material is not for human consumption. Selling otherwise creates legal exposure for both the vendor and the buyer.
For the broader regulatory backdrop, the FDA July 2026 peptide compounding review covers which peptides PCAC is voting on for the 503A bulks list and which are explicitly off-list.
Risk signals on suspect listings
Several patterns recur across the listings worth avoiding:
- No COA at all. A vendor that markets "lab-tested" without publishing the document has not actually closed the loop. The loop is the document.
- One COA reused across many lots. If the test date is two years old and there has been no new batch in the meantime, that is not active QC.
- Unrealistic price. Real retatrutide synthesis at research grade has a floor cost. Listings priced 60% below the rest of the market for the same vial size should be treated as suspect until a recent third-party COA is provided.
- Vague test method. "HPLC and MS verified" with no purity number is a phrase, not a measurement. Ask for the actual integrated peak.
- No US-based shipping origin or customer support. Several offshore listings move through indirect drop-shipping. The vial ships, but recall and follow-up are not realistic.
Order checklist
A short pre-purchase checklist that takes 90 seconds:
- Open the vendor's COA library and find the lot you are about to buy.
- Verify HPLC purity is 98% or higher and the date is within the last 12 months.
- Confirm the discount code applies to the specific product (ENHANCED works on Ascension).
- Cross-reference the listed vial size against the retatrutide dosage chart for the protocol you intend to run.
- Place the order from a US-shipping vendor when possible to keep return and customer-support paths open.
Ready to source? The Ascension partner page deep-links straight to the active R-10 and R-30 listings with ENHANCED pre-applied at checkout.
FAQ
Is retatrutide legal to buy in 2026?
Retatrutide is legal to sell and buy in the United States for research use only. It is not FDA-approved, is not available by prescription, and is not legal to compound under 503A. Vendors that ship retatrutide do so under research-use disclosures; the buyer assumes responsibility for that framing.
What is the difference between R-10 and R-30?
R-10 and R-30 refer to the lyophilized peptide mass per vial: 10 mg and 30 mg respectively. R-30 is more efficient at the higher end of the dosing ramp because each vial covers more weeks; R-10 is easier to handle in the first 4–6 weeks of titration. Most TRIUMPH-style protocols use both: R-10 for early titration and R-30 once weekly dosing exceeds 6 mg.
How do I verify a retatrutide COA is real?
Match the lot number on the vial label to the lot number on the certificate. Confirm the test method is HPLC and the reported purity is a quantitative number (e.g. 99.79%), not a marketing range (e.g. "≥99%"). Confirm the test date is within the last 12 months and the document names a specific independent third-party laboratory. If any of those checks fail, the COA is decorative.
Can I get retatrutide on a telehealth prescription?
Not legitimately as of May 2026. The FDA has not approved retatrutide and compounding pharmacies cannot legally compound it. Telehealth services that advertise "retatrutide" are usually routing to compounded tirzepatide or semaglutide under a misleading label. If the service quotes a prescription for retatrutide, ask which compounding pharmacy is producing it; the answer determines whether the prescription is real.
What dosage of retatrutide should I research?
The TRIUMPH program titrated from 2 mg weekly to a maximum of 12 mg weekly over 12 weeks. The full week-by-week ramp lives at the 12-week titration protocol. Subcutaneous injection in the abdomen, thigh, or upper arm with rotation between sites is standard.
Is the ENHANCED code real and current?
Yes. ENHANCED is a 50%-off code on the entire Ascension Peptides catalog, applied at checkout. It has been the partner code for the duration of this site and rolls forward without expiration. We disclose this is an affiliate relationship; we earn a commission when ENHANCED is used on a checkout that originates from this site.
What is the cheapest legitimate retatrutide source?
After the 50% ENHANCED discount, Ascension Peptides is competitive on per-mg pricing relative to the rest of the field with published per-lot COAs. Listings that beat that price by a wide margin almost always lack the COA library that justifies the higher trust tier. The vendor comparison table shows the trade-off in one view.
Where can I see the actual COA images for the lot I am buying?
The Ascension public library at https://ascensionpeptides.com/certificates-of-analysis/ lists every lot with a clickable certificate image. Our retatrutide page in the lab-tests database embeds direct links to each individual COA we have indexed, including R-10 and R-30 lots from January 2026 and earlier.
Continue researching
For deeper context on retatrutide specifically, the retatrutide research guide covers mechanism, half-life, storage, and FAQ. The retatrutide vs tirzepatide vs semaglutide comparison is the head-to-head against the rest of the GLP-1 field. For the dosing ramp, the 12-week titration protocol and the retatrutide dosage chart cover the full schedule. To verify any individual lot before purchase, jump straight to the retatrutide lab-tests page.
This article is for educational and research purposes only. Retatrutide is not FDA-approved as of May 2026, is not available by prescription, and is not for human consumption. Discussion of dosage, route, and protocol reflects what is reported in the cited clinical literature; nothing in this article is medical advice. Consult a qualified clinician for individual medical questions. We earn an affiliate commission on Ascension Peptides purchases that originate from this site; the editorial position would be the same without that commission.
